Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients; a randomized, double-blind placebo-controlled clinical trial by افشاری, مژگان et al.
Dossier: Diabetes: basic research and clinical approach
Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic
patients; a randomized, double-blind placebo-controlled clinical trial
MojganAfshari a, Bagher Larijani a, Ali Rezaie b, Alireza Mojtahedi a,
Mohammad Jafar Zamani b, FatemehAstanehi-Asghari b, Sara Mostafalou b,
Arash Hosseinnezhad a, Ramin Heshmat a, MohammadAbdollahi b,*
a Endocrine and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran
b Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
Received 29 September 2004; accepted 30 September 2004
Available online 04 November 2004
Abstract
The objective of this randomized, double-blind placebo-controlled clinical trial was to evaluate the value of allopurinol treatment on
reduction of oxidative stress in patients with diabetes type II patients. Forty-one diabetic type II subjects were randomly assigned to two
groups. One group (n = 20) received 100 mg allopurinol three times a day for 14 days and the other group (n = 21) received a placebo. Blood
and saliva samples were collected before and after intervention for analysis of lipid peroxidation level and total antioxidant power as indices
of oxidative stress. At the beginning of the study, the groups were similar based upon age, duration of diabetes, fasting glucose, and HbA1c.
Both allopurinol and placebo were effective in reduction of lipid peroxidation and total antioxidant power whether in saliva or plasma in a
similar extent. HbA1c and FBS levels did not change through the study neither in case or placebo group. It is concluded that allopurinol therapy
is not more effective than placebo in reduction of oxidative stress in diabetic patients. The same trend of changes in blood and saliva shown for
oxidative stress indices was interesting and suggests a chance for saliva to be valuable in diagnosis of oxidative stress. However, to elaborate
the exact role of allopurinol in diabetes, further large randomized clinical trials are needed.
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1. Introduction
Reactive oxygen species (ROS) and disturbed antioxidant
status have been reported in diabetes [1–4]. Occurrence of
oxidative stress in diabetes is probably due to the abnormal
metabolic milieu such as hyperglycemia, dyslipidemia and
elevated free fatty acids (FFA), which commonly occur in
diabetic patients [5–8]. In cultured vascular cells, elevating
glucose levels in the media has been shown to enhance
oxidant production including gluco-oxidants, glycated com-
pounds, oxidized LDL, superoxidants, and nitrotyrosine
[5,9–12]. Oxidative stress contributes to the development of
microvascular (i.e. retinopathy and nephropathy) and cardio-
vascular diseases associated with diabetes type I and II [1–4].
In addition, oxidative stress has been suggested to cause
abnormalities in secretion and action of insulin [13,14].
Thus, antioxidant therapy may prevent the main compli-
cations of diabetes. The beneﬁcial effects of antioxidants,
such as vitamin C, vitamin E, b-carotene, and lipoic acids
have been reported in cultured vascular cell, animal models
of diabetes and in patients with diabetes [15–20]. However,
supportive evidence that antioxidants can provide beneﬁcial
effects in diabetes in clinical trials is lacking.
One of the main mechanisms of ROS production and
atherosclerosis in diabetes is thought to be mediated by
xanthine oxidase [21]. Xanthine oxidase, is formed from
xanthine dehydrogenase through either proteolytic cleavage
or by oxidation of cysteines. Both xanthine oxidase and
xanthine dehydrogenase convert hypoxanthine to xanthine
and of xanthine to uric acid. However, xanthine oxidase has
the unique property of being able to reduce oxygen to form
superoxide and hydrogen peroxide. Xanthine oxidase is
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